Gland Pharma Grants 85,317 Employee Stock Options to Two Employees Under ESOP 2025
Options vest in three installments starting November 16, 2027, with exercise prices ranging from INR 1 to INR 1,692.95
Gland Pharma Limited approved the grant of 85,317 employee stock options to 2 employees under its Employee Stock Option Scheme 2025, with a vesting schedule over three years and exercise price based partly on market price and partly on face value. The options vest starting November 16, 2027, and can be exercised within two years of vesting.
Gland Pharma Limited
Corporate Action
Gland Pharma Limited's ESOP Compensation Committee approved granting 85,317 employee stock options to two employees under the ESOP 2025 scheme, with a detailed vesting schedule and pricing formula.
The stock options are granted under SEBI regulations governing share-based employee benefits and sweat equity, aligning with compliance requirements.
Out of the total options, 56,309 options are priced at INR 1,692.95 each, which is 50% of the equity share closing price on the National Stock Exchange as of the grant date, November 16, 2026.
The remaining 29,008 options are priced at the face value of INR 1 each.
The vesting schedule begins one year after the grant date, with 34% vesting on November 16, 2027, followed by 33% vesting each on November 16, 2028 and November 16, 2029, respectively.
Employees have up to two years from each vesting date to exercise their options under the scheme administered by the ESOP Compensation Committee.
Highlights
- Total of 85,317 stock options granted to 2 employees under ESOP 2025.
- 56,309 options priced at INR 1,692.95; 29,008 options priced at INR 1 (face value).
- Vesting occurs in three tranches over three years starting November 16, 2027.
- Options must be exercised within two years of respective vesting date.
- Grant complies with SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.
Key Data Snapshot
What happened
- Gland Pharma's ESOP Compensation Committee approved the grant of 85,317 employee stock options to 2 employees.
- This grant was approved at a meeting held on November 16, 2026.
- The options are granted under the Employee Stock Option Scheme (ESOP) 2025 of Gland Pharma.
- The grant is in accordance with SEBI regulations on share-based employee benefits and sweat equity.
Key details
- 56,309 options are priced at INR 1,692.95, which is 50% of the equity share closing price on NSE on grant date.
- 29,008 options are priced at INR 1, equal to face value of the equity share.
- Vesting occurs in three phases: 34% after 1 year, 33% after 2 years, and 33% after 3 years from the grant date.
- Employees have up to two years post vesting to exercise the options.
- The scheme is managed by the ESOP Compensation Committee of the Board.
Regulatory and governance context
- The grant complies with the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021 as amended.
- Required disclosures are made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Highlights
- Total of 85,317 stock options granted to 2 employees under ESOP 2025.
- 56,309 options priced at INR 1,692.95; 29,008 options priced at INR 1 (face value).
- Vesting occurs in three tranches over three years starting November 16, 2027.
- Options must be exercised within two years of respective vesting date.
- Grant complies with SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.
Disclosures
- SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Corporate Action
View allLatest corporate announcements and market updates in Corporate Action.
Kothari Industrial Corporation Proposes to Double Borrowing Limit to ₹1,000 Crore with Shareholder Vote via Postal Ballot
Kothari Industrial Corporation Limited has notified shareholders of a proposed special resolution to increase its borrowing limit from ₹500 crore to ₹1,000 crore and to authorize creating mortgages or charges on company properties as security. The company has initiated a postal ballot process with electronic voting from November 18 to December 17, 2026.
Read Full StoryBosch Home Comfort India Names Sangeetha Chhajed as Independent Director, Approves INR 400 Crore Related Party Deal
Bosch Home Comfort India Limited plans to appoint Mrs. Sangeetha Chhajed as an Independent Director with a term from October 1, 2026 to September 30, 2031. The company also seeks shareholder approval for material related party transactions with Highly Electrical Appliances India Pvt. Ltd., setting a financial limit of INR 400 crores per financial year until the 2027 Annual General Meeting.
Read Full StoryGland Pharma Allots 3,739 Equity Shares to Employees Under ESOP Scheme
Gland Pharma Limited allotted 3,739 equity shares to two employees upon exercise of stock options under its Employee Stock Option Scheme 2025, raising its total issued share capital to Rs. 16,50,14,593 as of November 16, 2026.
Read Full Story